JPS60218320A - オピオイド拮抗体の生長調整関連用途 - Google Patents
オピオイド拮抗体の生長調整関連用途Info
- Publication number
- JPS60218320A JPS60218320A JP59120630A JP12063084A JPS60218320A JP S60218320 A JPS60218320 A JP S60218320A JP 59120630 A JP59120630 A JP 59120630A JP 12063084 A JP12063084 A JP 12063084A JP S60218320 A JPS60218320 A JP S60218320A
- Authority
- JP
- Japan
- Prior art keywords
- growth
- tumor
- group
- animals
- opioid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003401 opiate antagonist Substances 0.000 title claims description 18
- 230000026267 regulation of growth Effects 0.000 title description 11
- 241001465754 Metazoa Species 0.000 claims description 83
- 230000012010 growth Effects 0.000 claims description 78
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 50
- 229960003086 naltrexone Drugs 0.000 claims description 50
- 102000003840 Opioid Receptors Human genes 0.000 claims description 48
- 108090000137 Opioid Receptors Proteins 0.000 claims description 48
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 24
- 229960004127 naloxone Drugs 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 17
- 239000005557 antagonist Substances 0.000 claims description 14
- 239000002207 metabolite Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 100
- 241000699670 Mus sp. Species 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 70
- 238000000034 method Methods 0.000 description 44
- 230000000694 effects Effects 0.000 description 39
- 241000700159 Rattus Species 0.000 description 38
- 238000012360 testing method Methods 0.000 description 37
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 36
- 230000004083 survival effect Effects 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 32
- 230000037396 body weight Effects 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 27
- 230000004044 response Effects 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 239000008223 sterile water Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- 229960005181 morphine Drugs 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 206010029260 Neuroblastoma Diseases 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000001133 acceleration Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 11
- 230000009036 growth inhibition Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 210000001638 cerebellum Anatomy 0.000 description 9
- 229940005483 opioid analgesics Drugs 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000005748 tumor development Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 239000003887 narcotic antagonist Substances 0.000 description 6
- 229940127240 opiate Drugs 0.000 description 6
- 210000004789 organ system Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 108010049140 Endorphins Proteins 0.000 description 5
- 102000009025 Endorphins Human genes 0.000 description 5
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 229960002069 diamorphine Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000005868 ontogenesis Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001385733 Aesculus indica Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000004092 somatosensory cortex Anatomy 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010092674 Enkephalins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000877 corpus callosum Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000005264 electron capture Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- -1 leucine enkephalins Chemical class 0.000 description 2
- 230000003137 locomotive effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000029052 metamorphosis Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000011206 morphological examination Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- IFGIYSGOEZJNBE-KNLJMPJLSA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 IFGIYSGOEZJNBE-KNLJMPJLSA-N 0.000 description 1
- XQQRNWNMEFUSMN-UTWDOOMRSA-N (4r,4as,7e,7ar,12bs)-7-hydrazinylidene-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 XQQRNWNMEFUSMN-UTWDOOMRSA-N 0.000 description 1
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- XETRHNFRKCNWAJ-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoyl 2,2,3,3,3-pentafluoropropanoate Chemical compound FC(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)F XETRHNFRKCNWAJ-UHFFFAOYSA-N 0.000 description 1
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 238000001367 Mood's median test Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009034 developmental inhibition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940068938 morphine injection Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/598,092 US4689332A (en) | 1984-04-09 | 1984-04-09 | Growth regulation and related applications of opioid antagonists |
| US598092 | 1984-04-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60218320A true JPS60218320A (ja) | 1985-11-01 |
| JPH0564125B2 JPH0564125B2 (https=) | 1993-09-14 |
Family
ID=24394194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59120630A Granted JPS60218320A (ja) | 1984-04-09 | 1984-06-11 | オピオイド拮抗体の生長調整関連用途 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4689332A (https=) |
| JP (1) | JPS60218320A (https=) |
| CA (1) | CA1228814A (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
| US5629349A (en) * | 1991-07-16 | 1997-05-13 | Minnesota State University System Through Its Mankato State University Agency | Compounds for modulating growth of infectious agents |
| US20010049375A1 (en) | 2000-03-15 | 2001-12-06 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
| EP3173082A1 (en) * | 2002-05-17 | 2017-05-31 | Duke University | Method for treating obesity |
| US7501433B2 (en) * | 2002-05-17 | 2009-03-10 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| EP1617832B1 (en) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| US8017622B2 (en) * | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
| US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| DK2089005T3 (da) | 2006-11-09 | 2010-07-19 | Orexigen Therapeutics Inc | Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag |
| CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
| SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| GB201704911D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| GB201704909D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
-
1984
- 1984-04-09 US US06/598,092 patent/US4689332A/en not_active Expired - Lifetime
- 1984-06-11 JP JP59120630A patent/JPS60218320A/ja active Granted
- 1984-06-20 CA CA000456996A patent/CA1228814A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1228814A (en) | 1987-11-03 |
| JPH0564125B2 (https=) | 1993-09-14 |
| US4689332A (en) | 1987-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60218320A (ja) | オピオイド拮抗体の生長調整関連用途 | |
| US5426112A (en) | Growth regulation and related applications of opioid antagonists | |
| EP1100589B1 (en) | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity | |
| Euchner-Wamser et al. | A model of cardiac nociception in chronically instrumented rats: behavioral and electrophysiological effects of pericardial administration of algogenic substances | |
| Wikler | Studies on the action of morphine on the central nervous system of cat | |
| JP7026245B2 (ja) | 鎮痛活性を有するポリペプチドおよびその応用 | |
| Gibb et al. | Tactile stimulation promotes motor recovery following cortical injury in adult rats | |
| Stern | Nursing posture is elicited rapidly in maternally naive, haloperidol-treated female and male rats in response to ventral trunk stimulation from active pups | |
| CN118593457B (zh) | 芬戈莫德在制备治疗缺血性脑卒中口鼻吸入制剂中的应用 | |
| Puniak et al. | Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma | |
| McLaughlin et al. | Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects | |
| CN115745890B (zh) | 一种酯键化合物及其制备方法和应用、镇痛药物 | |
| CN112494505B (zh) | 松果菊苷在制备治疗神经病理性疼痛药物中的用途 | |
| CN113912675A (zh) | 一种具有镇痛活性的蜈蚣多肽及其应用 | |
| Fung et al. | The importance of calcium in amphetamine-induced turning behavior in mice with unilateral nigro-striatal lesions | |
| Sinha et al. | Cat brain amine content during sleep | |
| CN117427083A (zh) | 阿洛酮糖在制备治疗阿尔兹海默病药物中的应用及药物 | |
| CN104784627B (zh) | 一种用于治疗外科开放性或闭合性损伤的中药外用膜剂及其制备方法 | |
| Olson et al. | Behavioral effects of D-Ala2-β-endorphin in squirrel monkeys | |
| CN103169716A (zh) | 用于治疗疼痛的复方药物组合 | |
| JPH08512326A (ja) | 免疫調節、補強治療のための製剤組成物 | |
| CN117143351B (zh) | 用于治疗脊髓损伤的Zn-MOF及其制备方法和应用 | |
| Blackburn et al. | Excitotoxic lesions of the prefrontal cortex attenuate the potentiation of amphetamine-induced locomotion by repeated neurotensin receptor activation | |
| Secrest et al. | Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats | |
| CN121843702A (zh) | 化合物用于治疗pros谱系疾病的用途 |